CD70 CAR-T by UTC Therapeutics for Mantle Cell Lymphoma: Likelihood of Approval

CD70 CAR-T is under clinical development by UTC Therapeutics and is currently in the Phase II in clinical pathway.

Aug 10, 2023 - 20:00

CD70 CAR-T is under clinical development by UTC Therapeutics and is currently in the Phase II in clinical pathway.

Read the original article

Tags:

Previous Article

CD70 CAR-T by UTC Therapeutics for Burkitt Lymphoma: Likelihood of Approval

Merck and Ginkgo Forge $490 Million Partnership to Enhance Biologics Manufacturi...

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Rituximab biosimilar by Celltrion for Waldenstrom Macro...

Nov 2, 2023

IN8bio cuts staff and pipeline to focus on AML cell therapy

IN8bio cuts staff and pipeline to focus on AML cell the...

Sep 6, 2024

Coherus allies with Mark Cuban to challenge AbbVie for Humira biosimilar

Coherus allies with Mark Cuban to challenge AbbVie for ...

Jun 3, 2023